Vaccine-associated paralytic poliomyelitis: A review of the epidemiology and estimation of the global burden

Journal of Infectious Diseases

Volumn 210, Issue , 2014, Pages S380-S389

  Platt, Lauren R ^a   Estivariz, Concepcion F ^b   Sutter, Roland W ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

inactivated poliovirus vaccine (IPV); OPV cessation; OPV withdrawal; oral poliovirus vaccine (OPV); polio endgame; polio eradication; poliomyelitis; vaccine associated paralytic poliomyelitis (VAPP)

Indexed keywords

ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE;

ARTICLE; DRUG SAFETY; HUMAN; INCOME; POLIOMYELITIS; PREVALENCE; RISK ASSESSMENT; TREND STUDY; VACCINATION REACTION; VACCINE ASSOCIATED PARALYTIC POLIOMYELITIS; ADOLESCENT; ADULT; CHILD; DEVELOPED COUNTRY; DEVELOPING COUNTRY; FEMALE; HEALTH; INFANT; MALE; NEWBORN; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; FEMALE; GLOBAL HEALTH; HUMANS; INFANT; INFANT, NEWBORN; MALE; POLIOMYELITIS; POLIOVIRUS VACCINES; PREVALENCE; RISK ASSESSMENT; YOUNG ADULT;

EID: 84910640291     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu184     Document Type: Article

References (45)

1. Minor P. Vaccine-derived poliovirus (VDPV): impact on poliomyelitis eradication. Vaccine 2009; 27:2649-52.
2. Dowdle WR,De Gourville E,Kew OM,Pallansch MA,Wood DJ. Polio eradication: the OPV paradox. Rev Med Virol 2003 13, 277-91.
3. Shahmahmoodi S, Mamishi S, Aghamohammadi A, et al. Vaccine-Associated paralytic poliomyelitis in immunodeficient children, Iran, 1995- 2008. Emerg Infect Dis 2010; 16:1133-6.
4. Nkowane BM, Wassilak SG, Orenstein WA, et al. Vaccine-Associated paralytic poliomyelitis: United States: 1973 through 1984. JAMA 1987; 257:1335-40.
5. Má s Lago P, Ferrer H, Goyenechea A, et al. Casos de poliomielitis paralítica asociada a la vacuna oral antipoliomielítica en Cuba (1963-2006). Rev Cuba Hig Epidemiol 2008; 46:1-14.
6. Estívariz CF, Molnár Z, Venczel L, et al. Paralytic poliomyelitis associated with Sabin monovalent and bivalent oral polio vaccines in Hungary. Am J Epidemiol 2011; 174:316-25.
7. Ministry of Health, Labour and Welfare of Japan. Present and Future vaccination of OPV in Japan [Internet]. http://www1.mhlw.go.jp/topics/polio/tp0831-1-c-11.html. Accessed 31 May 2013.
8. Schonberger LB, McGowan JE, Gregg MB. Vaccine-Associated poliomyelitis in the United States, 1961- 1972. Am J Epidemiol 1976; 104: 202-11.
9. Strebel PM, Ion-Nedelcu N, Baughman AL, Sutter RW, Cochi SL. Intramuscular injections within 30 days of immunization with oral poliovirus vaccine-A risk factor for vaccine-Associated paralytic poliomyelitis. N Engl J Med 1995; 332:500-6.
10. Sutter RW, Kew OM, Cochi SL, Aylward RB. Poliovirus vaccine-live. In: Plotkin SA, OrensteinWA, Offit PA, eds. Vaccines. 6th ed. Philadelphia, PA: Elsevier Saunders, 2013:598-645.
11. Meet ing of the Strategic Advisory Group of Experts on Immunization, November 2012-conclusions and recommendations. Wkly Epidemiol Rec 2013; 88:1-16.
12. Bonnet M-C, Dutta A. World wide experience with inactivated poliovirus vaccine. Vaccine 2008; 26:4978-83.
13. WattigneyWA, Mootrey GT, Braun MM, Chen RT. Surveillance for poliovirus vaccine adverse events, 1991 to 1998: impact of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Pediatrics 2001; 107:e83.
14. Population Division, Department of Economic and Social Affairs, United Nations. World Population Prospects: The 2010 Revision, CD-ROM Edition, 2011.
15. World Bank List of Economies [Internet]. The World Bank, 2012 http://www.healthsystemsglobal.org/Portals/0/files/World-bank-list-july2012.pdf. Accessed 12 August 2013.
16. Diamanti E, Ibrahimi B, Tafaj F, et al. Surveillance of suspected poliomyelitis in Albania, 1980- 1995: suggestion of increased risk of vaccine associated poliomyelitis. Vaccine 1998; 16:940-8.
17. Samo ? lovich EO, Feldman EV, Yermalovich MA, Protas II, Titov LP. Vaccine-Associated paralytic poliomyelitis and other diseases with acute flaccid parlysis syndrome in Bela rus. Cent Eur J Publ Heal 2003; 11:213-18.
18. de Oliveira LH, Struchiner CJ. Vaccine-Associated paralytic poliomyelitis: a retrospective cohort study of acute flaccid paralyses in Brazil. Int J Epidemiol 2000; 29:757-63.
19. de O liveira LH, Struchiner CJ. Vaccine-Associated paralytic poliomyelitis in Brazil, 1989- 1995. Rev Panam Salud Pública 2000; 7:219-24.
20. Dias-Tosta E, Kü ckelhaus CS. Guillain Barré syndrome in a population less than 15 years old in Brazil. Arq Neuropsiquiatr 2002; 60:367-73.
21. Teixeira-Rocha ES, Carmo EH, Tavares-Neto J. The occurrence of vaccine-Associated paralytic poliomyelitis in Brazil, 1995 to 2001. Rev Panam Salud Pú blica Pan Am J Public Heal 2005; 18:21-4.
22. Varughese PV, Carter AO, Acres SE, Furesz J. Eradication of indigenous poliomyelitis in Canada: impact of immunization strategies. Can J Public Heal Rev Can Santé Publique 1989; 80:363-8.
23. Alvis N, De la Hoz F, Narváez J. Economic impact of introducing the injectable inactivated polio vaccine in Colombia. Rev Panam Salud Pú blica 2010; 27:352-9.
24. Driesel G, Diedrich S, Künkel U, Schreier E. Vaccine-Associated cases of poliomyelitis over a 30 year period in East Germany. Eur J E pidemiol 1995; 11:647-54.
25. Begg NT, Chamberlain R, Roebuck M. Paralytic poliomyelitis in England & Wales, 1970- 84. Epidemiol Infect 1987; 99:97-106.
26. Smith JWG, Wherry PJ. Poliomyelitis surveillance in England and Wales, 1969- 1975. Epidemiol Infect 1978; 80:155-67.
27. Joce R, Wood D, Brown D, Begg N. Paralytic poliomyelitis in England and Wales, 1985- 91. BMJ 1992; 305:79-82.
28. Domok I. Experiences associated with the use of live poliovirus vaccine in Hungary, 1959- 1982. Clin Infect Dis 1984; 6(Supplement 2):S413-8.
29. Kohler KA, Banerjee K, Gary HladyW, Andrus JK, Sutter RW. Vaccineassociated paralytic poliomyelitis in India during 1999: decreased risk despite massive use of oral polio vaccine. Bull World Health Organ 2002; 80:210-6.
30. Kohler KA, Banerjee K, Sutter RW. Further clarity on vaccineassociated paralytic polio in India. Bull World Health Organ 2002; 80:987-7.
31. Fiore L, Novello F, Simeoni P, et al. Surveillance of acute flaccid paralysis in Italy: 1996- 1997. Eur J Epidemiol 1999; 15:757-63.
32. Hao L, Toyokawa S, Kobayashi Y. Paralytic poliomyelitis in England and Wales, 1985- 91. Jpn J Infect Dis 2007; 61:100-3.
33. Andrus JK, Strebel PM, de Quadros CA, Olive JM. Risk of vaccine-Associated paralytic poliomyelitis in Latin America, 1989-91. Bull World Health Organ 1995; 73:33-40.
34. Orstavik I, Flugsrud LB, Lahelle O. Paralytic poliom yelitis in Norway since the introduction of trivalent oral vaccine: an epidemiological and virological study. Bull World Health Organ 1971; 45:733-9.
35. Strebel PM, Aubert-Combiescu A, Ion-Nedelcu N, et al. Paralytic poliomyelitis in Romania, 1984- 1992 evidence for a high risk of vaccineassociated disease and reintroduction of wild-virus infection. Am J Epidemiol 1994; 140:1111-24.
36. Ivanova OE, Eremeeva TP, Leshchinskaia EV, et al. Paralytic poliomyelitis in Russian Federation in 1998-2005. Zh Mikrobiol Epidemiol Immunobiol 2007; 5:37-44.
37. Strebel PM, Sutter RW, Cochi SL , et al. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-Associated disease. Clin Infect Dis 1992; 14:568-79.
38. The relation between acute persisting spinal paralysis and poliomyelitis vaccine (oral): results of a WHO enquiry. Bull World Health Organ 1976; 53:319-31.
39. The relation between acute persisting spinal paralysis and poliomyelitis vaccine-results of a ten-year enquiry. WHO Consultative Group. Bull World Health Organ 1982; 60:231-42.
40. Esteves K. Safety of oral poliomyelitis vaccine: results of a WHO enquiry. Bull World Health Organ 1988; 66:739-46.
41. Cockburn WC. The work of the WHOConsultative Group on Poliomyelitis Vaccines. Bull World Health Organ 1988; 66:143-54.
42. Patriarca PA,Wrig ht PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis 1991; 13:926-39.
43. Tebbens RJD, Pallansch MA, Kew OM, et al. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal 2006; 26:1471-505.
44. Kew OM, Wright PF, Agol VI, et al. Circulating vaccine-derived polioviruses: current state of knowledge. Bull World Health Organ 2004; 82:16-23.
45. Global Polio Eradication Initiative. Polio Eradication & Endgame Strategic Plan 2013-2018. World Health Organization.